Lymphoma Clinical Trials in Pittsburgh

Showing 301-320 of 571 trials

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

NCT02519270

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma (NHL)

Non-Hodgkin Lymphoma

Spectrum Pharmaceuticals, Inc62 participantsStarted May 2016

Santa Monica, California, United States • Pittsburgh, Pennsylvania, United States

COMPLETEDPhase 1/2< 1 mile

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

NCT02178722

The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.

Microsatellite-instability (MSI) High Colorectal Cancer (CRC)Endometrial CancerHead and Neck Cancer+11 more

Incyte Corporation444 participantsStarted Jul 2014

La Jolla, California, United States • Los Angeles, California, United States • Sacramento, California, United States +21 more locations

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Lymphoma Trials in Other Cities

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma

Double Cord Versus Haploidentical (BMT CTN 1101)

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma

Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy

A Study of LY3023414 in Participants With Advanced Cancer

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Other Conditions in Pittsburgh